好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

PRISM Registry: A Novel Tool To Estimate the Prevalence of Pseudobulbar Affect Symptoms
MS and Related Diseases
P03 - (-)
215
BACKGROUND: PBA is a neurological disorder of emotional expression, occurring secondary to a variety of neurological conditions and characterized by uncontrollable, inappropriate outbursts of laughing and/or crying. Although US prevalence of PBA is estimated at about 2 million persons, PBA is thought to be under-recognized. Disease registries are powerful tools for obtaining epidemiologic data.
DESIGN/METHODS: The PBA Registry Series (PRISM) was established to prospectively estimate the prevalence of PBA symptoms in a clinic sample. Participating centers had Institutional Review Board approval. Investigators were asked to enroll ?20 patients with Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), Parkinson's disease (PD), stroke, or traumatic brain injury (TBI); patients were not screened for depression or other psychiatric disorders. Participants (or their caregivers) completed the Center for Neurologic Study-Lability Scale (CNS-LS; validated as corresponding to physician diagnosis of PBA in ALS and MS at CNS-LS thresholds ?13 and ?17, respectively) and a scale assessing impact of their neurological condition on quality of life (QOL). Demographics and use of antipsychotic/antidepressant medications were also recorded.
RESULTS: The PRISM registry closed in September 2012 with 5290 participants. Of these, 1944(36.7%) had PBA symptoms defined as a CNS-LS score ? 13 (29.3%, AD;44.8% ALS; 45.8%, MS; 26.0%, PD; 37.8%, stroke; and 52.4%, TBI). Patients with CNS-LS ?13 reported a greater impact of their neurologic condition on QOL (6.7 ;0-to-10[11-point-scale]) than patients with CNS-LS<13 (4.7;P<0.0001; two-sample t-test), and greater use of antidepressants (non-tricyclics 38.9%, TCAs 18.6%) or antipsychotics (5.0%) versus participants with CNS-LS<13 (27.9%, 9.8%, 2.7%, respectively, P<0.0001 for all, Chi-square).
CONCLUSIONS: PRISM provides novel insight into PBA symptom prevalence by prospectively evaluating a large number of patients across diagnoses and clinical settings. Follow-on studies are planned.
Authors/Disclosures
Benjamin R. Brooks, MD, FAAN (Clinical Trials Planning LLC)
PRESENTER 		Dr. Brooks has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Mitsubishi Tanabe Pharma America. Dr. Brooks has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Medicinova. Dr. Brooks has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Brooks has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AB Science. Dr. Brooks has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ionis. Dr. Brooks has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Mitsubishi Tanabe Pharma America. The institution of Dr. Brooks has received research support from Mitsubishi TanabePharma America. Dr. Brooks has received personal compensation in the range of $0-$499 for serving as a Member Annual Surveillance Committee CDC National ALS Registry with Center for Disease Control Agency Toxic Substances Disease Registry. Dr. Brooks has a non-compensated relationship as a Member ALS Quality Measures Subcommittee with 好色先生 that is relevant to AAN interests or activities.
No disclosure on file
Jonathan L. Fellus, MD (Advanced Neurocare) No disclosure on file
Mazen M. Dimachkie, MD, FAAN (University of Kansas Medical Center) Dr. Dimachkie has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Dimachkie has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Octapharma. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ArgenX. Dr. Dimachkie has received personal compensation in the range of $0-$499 for serving as a Consultant for Catalyst. Dr. Dimachkie has received personal compensation in the range of $0-$499 for serving as a Consultant for Takeda. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medlink. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CSL Behring. Dr. Dimachkie has received personal compensation in the range of $0-$499 for serving as a Consultant for Astellas. Dr. Dimachkie has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Janssen. Dr. Dimachkie has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Dianthus. Dr. Dimachkie has received personal compensation in the range of $0-$499 for serving as a Consultant for TACT / Treat NMD. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cabaletta Bio. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Clinical Neurological Society of America, Inc . Dr. Dimachkie has received personal compensation in the range of $0-$499 for serving as a Consultant for Ig Society, Inc. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abcuro. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amicus. Dr. Dimachkie has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Horizon/Immunovant. Dr. Dimachkie has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for EMD Serono. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ipsen. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Nuvig. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for 好色先生 (AAN). Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM). Dr. Dimachkie has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Annexon Biosciences. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AstraZeneca. Dr. Dimachkie has received personal compensation in the range of $0-$499 for serving as a Consultant for Candid Therapeutics. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Creyon Bio, Inc.. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Nuvig Therapeutics. Dr. Dimachkie has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for UCB Biopharma. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Vertex Pharmaceuticals. Dr. Dimachkie has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Fortrea. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Kriya Therapeutics. The institution of Dr. Dimachkie has received research support from NIH. The institution of Dr. Dimachkie has received research support from The Myositis Association. The institution of Dr. Dimachkie has received research support from Biosensics. Dr. Dimachkie has received intellectual property interests from a discovery or technology relating to health care. Dr. Dimachkie has received intellectual property interests from a discovery or technology relating to health care. Dr. Dimachkie has received intellectual property interests from a discovery or technology relating to health care. Dr. Dimachkie has received publishing royalties from a publication relating to health care. Dr. Dimachkie has received publishing royalties from a publication relating to health care.
Daniel Kantor, MD, FAAN (Medical Partnership 4 MS+) Dr. Kantor has received personal compensation for serving as an employee of Gateway Institute for Brain Research. Dr. Kantor has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Bristol Myers Squibb. Dr. Kantor has a non-compensated relationship as a HAP with MSFous (MSF) that is relevant to AAN interests or activities. Dr. Kantor has a non-compensated relationship as a Medical Board with MS Views & News that is relevant to AAN interests or activities.
Randall Kaye, MD (Avanir Pharmaceuticals) No disclosure on file